Pearl appoints Charles Bramlage president and CEO
This article was originally published in Scrip
Executive Summary
Pearl Therapeutics, a privately held company developing combination therapies for the treatment of respiratory diseases, including chronic obstructive pulmonary disease and asthma, has named Charles Bramlage president and chief executive officer. Mr Bramlage previously held several executive positions at Covidien, most recently president of pharmaceutical products. He has also served as president of European operations at Valeant Pharmaceuticals International and as president and CEO of BattellePharma.